Marshall Wace North America L.P. Takes $561,000 Position in OncoMed Pharmaceuticals, Inc. (OMED)

Marshall Wace North America L.P. purchased a new stake in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 187,088 shares of the biopharmaceutical company’s stock, valued at approximately $561,000. Marshall Wace North America L.P. owned about 0.50% of OncoMed Pharmaceuticals at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. First Eagle Investment Management LLC lifted its holdings in OncoMed Pharmaceuticals by 37.6% in the 2nd quarter. First Eagle Investment Management LLC now owns 219,420 shares of the biopharmaceutical company’s stock valued at $731,000 after acquiring an additional 60,000 shares during the last quarter. LMR Partners LLP acquired a new stake in OncoMed Pharmaceuticals in the 2nd quarter valued at about $201,000. Metropolitan Life Insurance Co. NY acquired a new stake in OncoMed Pharmaceuticals in the 1st quarter valued at about $160,000. Highbridge Capital Management LLC lifted its holdings in OncoMed Pharmaceuticals by 34.6% in the 1st quarter. Highbridge Capital Management LLC now owns 49,372 shares of the biopharmaceutical company’s stock valued at $455,000 after acquiring an additional 12,698 shares during the last quarter. Finally, Bank of America Corp DE lifted its holdings in OncoMed Pharmaceuticals by 11.3% in the 1st quarter. Bank of America Corp DE now owns 156,596 shares of the biopharmaceutical company’s stock valued at $1,442,000 after acquiring an additional 15,850 shares during the last quarter. 51.72% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Marshall Wace North America L.P. Takes $561,000 Position in OncoMed Pharmaceuticals, Inc. (OMED)” was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this report on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The correct version of this report can be read at https://sportsperspectives.com/2017/09/13/marshall-wace-north-america-l-p-takes-561000-position-in-oncomed-pharmaceuticals-inc-omed.html.

OMED has been the subject of a number of research analyst reports. Jefferies Group LLC reissued a “buy” rating and issued a $5.00 price target on shares of OncoMed Pharmaceuticals in a report on Sunday, July 9th. Piper Jaffray Companies set a $5.00 price target on shares of OncoMed Pharmaceuticals and gave the company a “hold” rating in a report on Monday, July 10th. Finally, ValuEngine lowered shares of OncoMed Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. One research analyst has rated the stock with a sell rating, seven have given a hold rating and two have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $8.00.

Shares of OncoMed Pharmaceuticals, Inc. (NASDAQ OMED) opened at 4.51 on Wednesday. OncoMed Pharmaceuticals, Inc. has a 1-year low of $2.91 and a 1-year high of $12.58. The stock’s market capitalization is $169.71 million. The firm’s 50-day moving average is $4.08 and its 200-day moving average is $5.08.

OncoMed Pharmaceuticals (NASDAQ:OMED) last posted its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.50) by $0.10. The company had revenue of $6.20 million for the quarter, compared to analyst estimates of $6.08 million. OncoMed Pharmaceuticals’s quarterly revenue was down 7.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.91) earnings per share. On average, analysts predict that OncoMed Pharmaceuticals, Inc. will post ($1.85) earnings per share for the current fiscal year.

About OncoMed Pharmaceuticals

OncoMed Pharmaceuticals, Inc (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer’s growth, resistance, recurrence and metastasis. The Company’s therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11).

Institutional Ownership by Quarter for OncoMed Pharmaceuticals (NASDAQ:OMED)

Receive News & Ratings for OncoMed Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoMed Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply